DNA TwoPointO Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
DNA TwoPointO Inc. - overview
Established
2003
Location
Newark, CA, US
Primary Industry
Biotechnology
About
DNA TwoPointO Inc. is a biotechnology company specializing in advanced bioengineering solutions that enhance life science research and product development for its clients in the pharmaceutical and biotech sectors. Founded in 2003 and headquartered in Newark, US, DNA TwoPointO Inc. is focused on providing innovative solutions in bioengineering.
The company was established by Kalle Kaasinen, Sridhar Govindarajan, Tarik Batal, and Wael Mahmoud. Kalle Kaasinen serves as the CEO. Specific details regarding funding rounds or significant pivots in business strategy are not available. ATUM specializes in advanced bioengineering solutions that integrate various aspects of life science research and product development.
The company offers a collaborative approach, merging its expertise with that of its clients to enhance project outcomes. Core services include vector selection, sequence optimization, and the development of high-producing cell lines, which are critical for gene expression projects. Their client base primarily consists of biotechnology and pharmaceutical companies engaged in preclinical research, as well as those preparing for Investigational New Drug (IND) applications. ATUM's products are marketed globally, with a focus on North America and Europe, catering to a diverse array of end-users in the life sciences sector.
The revenue model for ATUM is rooted in B2B transactions, primarily through service agreements and collaborations with biotech and pharmaceutical partners. Clients typically engage with ATUM for customized solutions, which may include long-term projects or shorter engagements depending on their specific needs. The transaction structure involves direct partnerships, whereby clients may pay for individual services or enter into multi-phase agreements that encompass comprehensive project support from discovery through to manufacturing. While specific pricing details are not disclosed, the revenue is generated from the execution of these tailored projects, often centered around ATUM's flagship offerings in gene expression and cell line development.
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy
Website
www.atum.bio
Verticals
HealthTech
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.